Clin2Atlas
AtlasMetabolic, hormones & kidneysDiabetes and kidney diseases

Acute glomerulonephritis

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251994 — Budesonide approved (FDA)2011 — Belimumab approved (FDA)2021 — Voclosporin approved (FDA)2023 — Iptacopan approved (FDA)2023 — Sparsentan approved (FDA)
1994: Drug approval — Budesonide approved (FDA). 2011: Drug approval — Belimumab approved (FDA). 2021: Drug approval — Voclosporin approved (FDA). 2023: Drug approval — Iptacopan approved (FDA). 2023: Drug approval — Sparsentan approved (FDA)

What's being tested now

2008: 1 trials started2009: 2 trials started2010: 2 trials started2011: 1 trials started2012: 1 trials started2013: 3 trials started2014: 1 trials started2015: 1 trials started2016: 1 trials started2017: 1 trials started2018: 1 trials started2019: 4 trials started2020: 10 trials started2021: 10 trials started2022: 19 trials started2023: 26 trials started2024: 54 trials started2025: 80 trials started2026: 87 trials started20102020202687

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 291 active Acute Disease trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.